CytoMed Therapeutics income statement data for the quarter ended Dec 2025. This income statement covers 9 quarters of results from Dec 2021 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Dec2023 | Jun2024 | Dec2024 | Jun2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | |||||||||
| Non-interest income | |||||||||
| Asset Management | 0.03M | 0.05M | 0.03M | ||||||
| Non-Interest Income | 0.03M | 0.05M | 0.03M | ||||||
| Operating Items | |||||||||
| Amortization - Intangibles | 0.01M | 0.00M | 321.00 | 321.00 | |||||
| Depreciation & Amortization - TotalDep. & Amort. (Tot) | 0.13M | 0.15M | 0.12M | 0.08M | |||||
| Research & DevelopmentR&D | 0.60M | 0.81M | 0.24M | 0.28M | |||||
| Wages, Salaries and OtherWages | 0.04M | 0.04M | 0.01M | ||||||
| Operating ExpensesOpex | 0.73M | 0.96M | 0.36M | 0.37M | |||||
| Additional items | |||||||||
| Shares Outstanding | 6.93M | 6.93M | 7.92M | 7.92M | 10.63M | 10.63M | 11.54M | 11.54M | 11.65M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 6.93M | 6.93M | 7.92M | 7.92M | 10.63M | 10.63M | 11.54M | 11.54M | 11.65M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 7.48M | 7.92M | 11.54M | 11.54M | 11.83M |